Influence of neoadjuvant targeted therapy on renal functional in patients with localized renal cell carcinoma

Voilenko O.A.

Головна
Публікації
Influence of neoadjuvant targeted therapy on renal functional in patients with localized renal cell carcinoma

30 січня 2020

1156

Oncology, Hematology

Voilenko O.A.

Ключові слова :

glomerular filtration rate.,

neoadjuvant targeted therapy,

renal cell carcinoma,

renal function

Спеціальності :

Oncology, Hematology

Резюме

Objective — to determine the impact of neoadjuvant targeted therapy (NTT) on renal function in patients with localized renal cell carcinoma (RCC). Маterials and methods. 75 patients with localized RCC, who underwent two cycles of NTT in the period from 2017 to 2019, determining with serum creatinine, total glomerular filtration rate (GFR) by CKD-EPI and MDRD formulars and GFR on the RCC side according to dynamical renoscintigraphy. Results. Serum creatinine before and after NTT was 90.4±22.4 and 90.6±18.3 μmol/l, respectively (p=0.95). Statistically significant difference in the level of total GFR by the selected formulas was not found (p=0.8 and p=0.7, respectively). No differences between indices of separation GFR on the side of RCC lesion before and after NTT were found (46.5±12.9 and 47.4±15.6 ml/min, respectively; p=0.84). Conclusions. Carrying out two blocks of NTT to patients with localized RCC does not lead to a statistically significant decrease in serum creatinine (p=0.95), does not affect the level as total GFR (p=0.7) and GFR on the tumor side (p=0.84), and may be considered safe.

Published: 30.01.2020

References:

European Association of Urology (2018) Renal Cell Carcinoma (https://uroweb.org/guideline/renal-cell-carcinoma).
Go A.S., Chertow G.M., Fan D. et al. (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med., 351(13): 1296–1305. doi: 10.1056/NEJMoa041031.
Herzog C.A., Asinger R.W., Berger A.K. et al. (2011) Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int., 80(6): 572–586. doi: 10.1038/ki.2011.223.
Kamba T., McDonald D.M. (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer, 96(12): 1788–1795, doi: 10.1038/sj.bjc.6603813.
Lane B.R., Derweesh I.H., Kim H.L. et al. (2015) Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Urol. Oncol., 33(3): 112.e15–112.e21. doi: 10.1016/j.urolonc.2014.11.009.
Ljungberg B., Hanbury D.C., Kuczyk M.A. et al. (2007) EAU renal cell carcinoma guideline. Eur. Urol., 51(6): 1502–1510. doi: 10.1016/j.eururo.2007.03.035.
Margulis V., Matin S.F., Tannir N. et al. (2008) Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol., 180(1): 94–98. doi: 10.1016/j.juro.2008.03.047.
National Comprehensive Cancer Network (2019) Kidney cancer (https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf).
Rini B.I., Plimack E.R., Takagi T. et al. (2015) A phase II study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J. Urol., 194(2): 297–303. doi: 10.1016/j.juro.2015.03.096.
Silberstein J.L., Millard F., Mehrazin R. et al. (2010) Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int., 106(9): 1270–1276. doi: 10.1111/j.1464-410X.2010.09357.x.